Evofem's SOLOSEC submitted for regulatory approval in the UAE
Marks first international filing for Evofem’s single-dose oral treatment
Marks first international filing for Evofem’s single-dose oral treatment
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Subscribe To Our Newsletter & Stay Updated